KPV
Lysine-Proline-Valine, α-MSH (11-13)
Three-amino acid tail of α-MSH that carries the anti-inflammatory activity without the pigmentation effects. Used mostly for gut and skin inflammation.
Preclinical only
Not approved as a drug or supplement for any use. In July 2026 an FDA advisory committee recommended KPV for the section 503A bulks list - a recommendation about compounding eligibility, not a drug approval, and the FDA has not issued a final decision.
What it is
α-melanocyte stimulating hormone is an endogenous peptide with two largely separable properties: it drives pigmentation, and it is potently anti-inflammatory. KPV is the last three residues - lysine, proline, valine - and it retains the anti-inflammatory activity while dropping the melanocortin receptor binding that causes tanning.
That separation is the reason KPV exists as a distinct compound rather than a curiosity: you get the immune modulation without the pigmentation, appetite and libido effects of the parent hormone.
Mechanism
KPV acts intracellularly, which is unusual for a peptide this small. It is taken up by the PepT1 transporter - expressed in the intestinal epithelium and upregulated in inflamed colonic tissue - and once inside interferes with NF-κB signalling, the master transcriptional switch for inflammatory gene expression.
The PepT1 route is why oral KPV has a coherent rationale for gut conditions specifically. It is being absorbed by the exact transporter that inflamed intestinal tissue over-expresses, meaning the peptide concentrates where the inflammation is. That is a genuinely elegant mechanism - and it is also why oral KPV for a systemic complaint is a much weaker proposition.
The evidence position
The mechanistic work is real: mouse colitis models show reduced inflammation, reduced weight loss, and improved histology. Cell work supports the NF-κB mechanism.
There are no completed human clinical trials. The July 2026 advisory committee recommendation is a meaningful regulatory signal - a committee reviewed the safety and effectiveness data and found it adequate to permit compounding - but it is not approval and does not substitute for trial evidence of efficacy.
Practical notes
- Match route to target. Oral for gut, topical for skin, subcutaneous for systemic. The PepT1 mechanism does not apply outside the gut.
- Often stacked with BPC-157 for gut protocols, on the reasoning that one modulates inflammation while the other supports mucosal repair. Both are preclinical.
- Not a substitute for diagnosis. Chronic gut symptoms have differential diagnoses that include conditions where delay causes real harm.
Side effects and warning signs
Commonly reported
- Injection-site irritation
- Few side effects reported - but reporting is entirely informal and no safety study exists
Stop and get medical help
- Worsening gut symptoms rather than improvement - inflammatory bowel disease needs a real diagnosis and real treatment, and self-treating it delays both
- Signs of infection at an injection site
Sources
From the community
Discussion for this compound concentrates in r/Peptidesource and r/PeptideForum.
No threads cached yet.
Reddit removed unauthenticated API access, so this section is populated by a build-time script using your own API credentials. Run pnpm fetch:reddit with REDDIT_CLIENT_ID and REDDIT_CLIENT_SECRET set.